Alcon
Alcon Secures Control of Aurion Biotech in Strategic Takeover
Alcon, Aurion Biotech, majority stake, CEO replacement, cell therapy, corneal endothelial disease, AURN001, IPO dispute
Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans
Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery
Delaware Court Ruling Paves Way for Aurion Biotech IPO, Alcon to Appeal Decision
Aurion Biotech, Alcon Research, IPO, Delaware Court of Chancery, reverse stock split, voting proxy, Series C consent rights
Aurion Biotech Presses On with IPO Plans Amid Legal Dispute with Investor Alcon
Aurion Biotech, IPO, legal dispute, Alcon, cell therapy, biotech investment